Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(05): 470-478
DOI: 10.1055/s-0041-1732833
How I Treat

How I Treat Neuroendocrine Tumors

Aasems Jacob
1   Division of Medical Oncology, University of Kentucky, Lexington, Kentucky, United States
,
Gaby Gabriel
2   Department of Radiology, Division of Interventional Radiology, University of Kentucky, Lexington, Kentucky, United States
3   Division of Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States
,
Robert A. Ramirez
4   Department of Hematology and Oncology, Ochsner Health New Orleans, New Orleans, Louisiana, United States
,
Yi-Zarn Wang
5   Department of Surgery, Louisiana State University Health Science Center, New Orleans, Louisiana, United States
,
Lowell Anthony
1   Division of Medical Oncology, University of Kentucky, Lexington, Kentucky, United States
3   Division of Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States
,
Aman Chauhan
1   Division of Medical Oncology, University of Kentucky, Lexington, Kentucky, United States
3   Division of Medical Oncology, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States
› Author Affiliations Financial Disclosures A.C. receives research support from BMS, Clovis Oncology, EMD Serono, Nanopharmaceuticals, Tersera, ECS Progastrin. Advisor: Novartis, Ipsen, TerSera, Lexicon, Seneca Therapeutics, and ECS Progastrin. R.A.R. serves as a speaker for Merck & Co., Inc., Advanced Accelerator Applications, Genentech, Inc., AstraZeneca, and Ipsen Biopharmaceuticals, Inc. Consultant for Curium Pharma, Advanced Accelerator Applications, AstraZeneca, Ipsen Biopharmaceuticals and Novartis Pharmaceuticals, Corp. Research funding from Aadi Biosciences, and Merck & Co., Inc. Other coauthors do not have relevant disclosures.
› Further Information
Also available at
   Permissions and Reprints

Introduction

Neuroendocrine tumors (NETs) originate from diffuse neuroendocrine cell system and can develop in many organs. Gastroenteropancreatic (GEP) NETs account for approximately 70%, followed by bronchopulmonary and thymic NETs.[1] The World Health Organization (WHO) classification divides GEP NETs into well-differentiated NETs and poorly differentiated neuroendocrine carcinoma (NEC). Well-differentiated NETs can be grade 1 (G1; mitotic count <2 per 10 HPF - high power field, Ki-67 < 3%), G2 (mitotic count: 2–20, Ki-67: 3–20%) tumors, and G3 (mitotic count >20, Ki-67 > 20%).[2] Poorly differentiated NECs are always G3 tumors with >20 mitotic count and Ki-67 index >20% and include small- and large-cell NECs.[2] A total of 10 to 13% of NETs do not have a primary site identified at the time of diagnosis and are called NETs of unknown primary.[1] [3] NETs can also be differentiated based on the secretion of vasoactive amines and hormones into functional (30%) and nonfunctional NETs (70%).[1] This article focuses on the management of well-differentiated NETs with attention to systemic therapy. Factors influencing initial medical decision-making in NET management include functional status, stage, and grade, burden of metastatic disease, and symptoms at presentation.



Publication History

Article published online:
23 September 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Yao JC, Hassan M, Phan A. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
    CrossrefPubMedGoogle Scholar
  • 2 Nagtegaal ID, Odze RD, Klimstra D. et al. WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76 (02) 182-188
    CrossrefPubMedGoogle Scholar
  • 3 Catena L, Bichisao E, Milione M. et al. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?. Tumori 2011; 97 (05) 564-567
    CrossrefPubMedGoogle Scholar
  • 4 Sjöblom SM. Clinical presentation and prognosis of gastrointestinal carcinoid tumours. Scand J Gastroenterol 1988; 23 (07) 779-787
    CrossrefPubMedGoogle Scholar
  • 5 Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001; 12 (Suppl. 02) S69-S72
    CrossrefPubMedGoogle Scholar
  • 6 Rinke A, Wittenberg M, Schade-Brittinger C. et al. PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology 2017; 104 (01) 26-32
    CrossrefPubMedGoogle Scholar
  • 7 Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA. ELECT Study Group. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (elect): a randomized, double-blind, placebo-controlled trial. Endocr Pract 2016; 22 (09) 1068-1080
    CrossrefPubMedGoogle Scholar
  • 8 Ferolla P, Brizzi MP, Meyer T. et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2017; 18 (12) 1652-1664
    CrossrefPubMedGoogle Scholar
  • 9 Kulke MH, Ruszniewski P, Van Cutsem E. et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol 2019; 30 (11) 1846
    CrossrefPubMedGoogle Scholar
  • 10 Kulke MH, Hörsch D, Caplin ME. et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol 2017; 35 (01) 14-23
    CrossrefPubMedGoogle Scholar
  • 11 Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999; 94 (05) 1381-1387
    CrossrefPubMedGoogle Scholar
  • 12 Frankton S, Bloom SR. Gastrointestinal endocrine tumours. Glucagonomas. Baillieres Clin Gastroenterol 1996; 10 (04) 697-705
    CrossrefPubMedGoogle Scholar
  • 13 Wang YZ, Chauhan A, Rau J. et al. Neuroendocrine tumors (NETs) of unknown primary: is early surgical exploration and aggressive debulking justifiable?. Linchuang Zhongliuxue Zazhi 2016; 5 (01) 4
    Google Scholar
  • 14 Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford 2015; 17 (01) 17-22
    CrossrefPubMedGoogle Scholar
  • 15 Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á. et al. Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study. J Clin Oncol 2019; 37 (28) 2571-2580
    CrossrefPubMedGoogle Scholar
  • 16 Caplin ME, Pavel M, Ćwikła JB. et al. CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371 (03) 224-233
    CrossrefPubMedGoogle Scholar
  • 17 Glazer ES, Tseng JF, Al-Refaie W. et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford 2010; 12 (06) 427-433
    CrossrefPubMedGoogle Scholar
  • 18 Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res 2001; 95 (01) 8-12
    CrossrefPubMedGoogle Scholar
  • 19 Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26 (08) 985-990
    CrossrefPubMedGoogle Scholar
  • 20 Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P. NET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford 2015; 17 (01) 29-37
    CrossrefPubMedGoogle Scholar
  • 21 Kennedy AS, Dezarn WA, McNeillie P. et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31 (03) 271-279
    CrossrefPubMedGoogle Scholar
  • 22 Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I. et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review. Surgery 2017; 162 (03) 525-536
    CrossrefPubMedGoogle Scholar
  • 23 Yao JC, Fazio N, Singh S. et al. RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387 (10022) 968-977
    CrossrefPubMedGoogle Scholar
  • 24 Pavel ME, Hainsworth JD, Baudin E. et al. RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378 (9808) 2005-2012
    CrossrefPubMedGoogle Scholar
  • 25 Pavel ME, Baudin E, Öberg KE. et al. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol 2017; 28 (07) 1569-1575
    CrossrefPubMedGoogle Scholar
  • 26 Strosberg J, El-Haddad G, Wolin E. et al. NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
    CrossrefPubMedGoogle Scholar
  • 27 Brabander T, van der Zwan WA, Teunissen JJ. et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 2017; 23 (16) 4617-4624
    CrossrefPubMedGoogle Scholar
  • 28 Strosberg J, Wolin E, Chasen B. et al. NETTER-1 Study Group. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial. J Clin Oncol 2018; 36 (25) 2578-2584
    CrossrefPubMedGoogle Scholar
  • 29 Sonbol MB, Halfdanarson TR, Hilal T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol 2020; 6 (07) 1086-1092
    CrossrefPubMedGoogle Scholar
  • 30 Kulke MH, Lenz HJ, Meropol NJ. et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26 (20) 3403-3410
    CrossrefPubMedGoogle Scholar
  • 31 Grande E, Capdevila J, Castellano D. et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE. Ann Oncol 2015; 26 (09) 1987-1993
    CrossrefPubMedGoogle Scholar
  • 32 Capdevila J, Fazio N, Lopez CL. et al. Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs. J Clin Oncol 2019; 37 (15suppl) 4106
    CrossrefGoogle Scholar
  • 33 Iyer RV, Konda B, Fountzilas C. et al. Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. Cancer 2020; 126 (16) 3689-3697
    CrossrefPubMedGoogle Scholar
  • 34 Yao JC, Phan A, Hoff PM. et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26 (08) 1316-1323
    CrossrefPubMedGoogle Scholar
  • 35 Yao JC, Guthrie KA, Moran C. et al. Phase III prospective randomized comparison trial of depot octreotide plus interferon Alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol 2017; 35 (15) 1695-1703
    CrossrefPubMedGoogle Scholar
  • 36 Strosberg JR, Halfdanarson TR, Bellizzi AM. et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 2017; 46 (06) 707-714
    CrossrefPubMedGoogle Scholar
  • 37 Pavel M, O’Toole D, Costa F. et al. Vienna Consensus Conference participants. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016; 103 (02) 172-185
    CrossrefPubMedGoogle Scholar
  • 38 Faiss S, Pape UF, Böhmig M. et al. International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors–the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21 (14) 2689-2696
    CrossrefPubMedGoogle Scholar
  • 39 Arnold R, Rinke A, Klose KJ. et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3 (08) 761-771
    CrossrefPubMedGoogle Scholar
  • 40 Al-Toubah T, Morse B, Strosberg J. Capecitabine and temozolomide in advanced lung neuroendocrine neoplasms. Oncologist 2020; 25 (01) e48-e52
    CrossrefPubMedGoogle Scholar
  • 41 Kunz PL, Balise RR, Fehrenbacher L. et al. Oxaliplatin-fluoropyrimidine chemotherapy plus bevacizumab in advanced neuroendocrine tumors: an analysis of 2 phase II trials. Pancreas 2016; 45 (10) 1394-1400
    CrossrefPubMedGoogle Scholar
  • 42 Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Eastern Cooperative Oncology Group. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23 (22) 4897-4904
    CrossrefPubMedGoogle Scholar
  • 43 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38 (01) 1-10
    CrossrefPubMedGoogle Scholar
  • 44 Patel SP, Othus M, Chae YK. et al. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors. Clin Cancer Res 2020; 26 (10) 2290-2296
    CrossrefPubMedGoogle Scholar
  • 45 Newman CB, Melmed S, Snyder PJ. et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients–a clinical research center study. J Clin Endocrinol Metab 1995; 80 (09) 2768-2775
    CrossrefPubMedGoogle Scholar
  • 46 Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic Well-differentiated grade 3 neuroendocrine tumors: review and position statement. Oncologist 2016; 21 (10) 1191-1199
    CrossrefPubMedGoogle Scholar
  • 47 Basturk O, Yang Z, Tang LH. et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39 (05) 683-690
    CrossrefPubMedGoogle Scholar
  • 48 Walter T, Tougeron D, Baudin E. et al. CEPD investigators. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. Eur J Cancer 2017; 79: 158-165
    CrossrefPubMedGoogle Scholar
  • 49 Heetfeld M, Chougnet CN, Olsen IH. et al. other Knowledge Network members. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015; 22 (04) 657-664
    CrossrefPubMedGoogle Scholar
  • 50 Hijioka S, Hosoda W, Matsuo K. et al. Rb Loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study. Clin Cancer Res 2017; 23 (16) 4625-4632
    CrossrefPubMedGoogle Scholar
  • 51 Panzuto F, Merola E, Pavel ME. et al. Stage IV gastro-entero-pancreatic neuroendocrine neoplasms: a risk score to predict clinical outcome. Oncologist 2017; 22 (04) 409-415
    CrossrefPubMedGoogle Scholar
  • 52 Basu SPR, Ranade R, Thapa P. Peptide receptor radionuclide therapy in the management of neuroendocrine tumors (Neoplasms)*: Fundamentals and salient clinical practice points for medical oncologists. Indian J Med Paediatr Oncol 2019; 40: 165-167
    Article in Thieme ConnectGoogle Scholar
  • 53 Yao JC, Pavel M, Lombard-Bohas C. et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol 2016; 34 (32) 3906-3913
    CrossrefPubMedGoogle Scholar
  • 54 Medley L, Morel AN, Farrugia D. et al. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 2011; 104 (07) 1067-1070
    CrossrefPubMedGoogle Scholar
  • 55 Bajetta E, Catena L, Procopio G. et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemother Pharmacol 2007; 59 (05) 637-642
    CrossrefPubMedGoogle Scholar
  • 56 Mitry E, Walter T, Baudin E. et al. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)–a phase II non-randomised trial. Eur J Cancer 2014; 50 (18) 3107-3115
    CrossrefPubMedGoogle Scholar
  • 57 Ekeblad S, Sundin A, Janson ET. et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13 (10) 2986-2991
    CrossrefPubMedGoogle Scholar
  • 58 Crona J, Fanola I, Lindholm DP. et al. Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology 2013; 98 (02) 151-155
    CrossrefPubMedGoogle Scholar
  • 59 Fine RL, Gulati AP, Krantz BA. et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 2013; 71 (03) 663-670
    CrossrefPubMedGoogle Scholar
  • 60 Fine RL, Gulati AP, Tsushima D. et al. Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors. J Clin Oncol 2014; 32 (Suppl. 03) 179
    CrossrefGoogle Scholar
  • 61 Strosberg JR, Fine RL, Choi J. et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117 (02) 268-275
    CrossrefPubMedGoogle Scholar
  • 62 Chan JA, Stuart K, Earle CC. et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012; 30 (24) 2963-2968
    CrossrefPubMedGoogle Scholar
  • 63 Mehnert JM, Bergsland E, O’Neil BH. et al. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study. Cancer 2020; 126 (13) 3021-3030
    CrossrefPubMedGoogle Scholar
  • 64 Strosberg J, Mizuno N, Doi T. et al. Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study. Clin Cancer Res 2020; 26 (09) 2124-2130
    CrossrefPubMedGoogle Scholar